1. Home
  2. HOWL vs NSRX Comparison

HOWL vs NSRX Comparison

Compare HOWL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.61

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$7.51

Market Cap

63.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOWL
NSRX
Founded
2017
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.5M
63.4M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
HOWL
NSRX
Price
$0.61
$7.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$6.50
$20.50
AVG Volume (30 Days)
935.7K
5.8K
Earning Date
11-04-2025
02-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.56
$5.90
52 Week High
$2.38
$9.99

Technical Indicators

Market Signals
Indicator
HOWL
NSRX
Relative Strength Index (RSI) 30.66 N/A
Support Level $0.59 N/A
Resistance Level $0.74 N/A
Average True Range (ATR) 0.09 0.00
MACD -0.02 0.00
Stochastic Oscillator 8.02 0.00

Price Performance

Historical Comparison
HOWL
NSRX

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: